KARO BIO PRESENTS POSITIVE KB2115 PHASE IIa PROOF OF CONCEPT DATA AT TWO MAJOR SCIENTIFIC MEETINGS

KARO BIO PRESENTS POSITIVE KB2115 PHASE IIa PROOF OF CONCEPT DATA AT TWO MAJOR
SCIENTIFIC MEETINGS

KB2115 induces a profound and clinically relevant lowering of a number of risk
factors for development of cardiovascular disease and was well tolerated in the
first clinical phase 2 study. Key data will now be presented at two scientific
meetings. The first presentation will be made later today, October 5, at the
DALM (Drugs Affecting Lipid Metabolism) meeting in New York. The second
presentation will be made on October 6 at the 78th Annual Meeting of the
American Thyroid Association in New York.

A separate press release including selective scientific data will be made public
on Monday, October 8, 2007. 

For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer 
Telephone: +46 8 608 60 20

Per Otteskog, Senior Vice President 
Telephone: +46 70 632 7527


Facts about Karo Bio 
Karo Bio is a drug discovery and development company specializing in nuclear
receptors for the development of novel pharmaceuticals with focus on metabolic
diseases. 

The company has expanded from being a drug discovery company by adding in-house
preclinical and clinical development resources and competence for development of
drugs to treat metabolic diseases. The company has a strong project portfolio
with innovative molecules that primarily targets diseases such as diabetes,
atherosclerosis and dyslipidemia. In all of these areas there are significant
market opportunities and a growing need for new pharmaceuticals with new
mechanisms of action. 

In addition to the proprietary projects Karo Bio has two strategic
collaborations with international pharmaceutical companies and one biotech
collaboration for development of innovative therapies for the treatment of
common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters:
KARO.ST).

This press release is also available online at: www.karobio.com and
www.newsroom.cision.com